
INMODE LTD
INMDNASDAQTrading Snapshot
- Day Range
- $14.95 β $15.26
- 52-Week Range
- $12.72 β $16.74
- Volume
- $1.87B
- Avg Volume
- $1.34B
- Shares Outstanding
- 57.5M
- Next Earnings
- Sep 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $370M
- Last Q Revenue
- $96M
- P/E Ratio
- 12.1
- P/S Ratio
- 2.3x
- EPS (TTM)
- $1.32
- Dividend Yield
- 0.00%
Why Investors Own INMD
- βHigh-growth profile β revenue up +16.4% YoY with expanding US Equity exposure.
- βHealthy economics β 53% gross margin and 28% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INMODE LTD
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

IDEXX Laboratories: Worth The Premium
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.
InMode (NASDAQ:INMD) Q2 Revenue Inline, EPS Beats; Shares Dip 2.5%
InMode Q2 revenue of $95.6M matches estimates, EPS beats at $0.35; shares slip 2.5% as growth stays flat.

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.
InMode Lowers FY2026 Adj EPS Guidance from $1.33-$1.38 to $1.29-$1.34 vs $1.34 Est; Affirms FY2026 Sales Guidance of $365.000M-$375.000M vs $370.301M Est
InMode (NASDAQ:INMD) lowers FY2026 Adj EPS guidance from $1.33-$1.38 to $1.29-$1.34 vs $1.34 analyst estimate. Affirms FY2026 sales outlook from $365.000 million-$375.000 million to $365.000 million-$375.000 million vs
InMode Q2 Adj. EPS $0.35 Beats $0.33 Estimate, Sales $95.589M Beat $93.032M Estimate
InMode (NASDAQ:INMD) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.33 by 6.06 percent. This is a 25.53 percent decrease over earnings of $0.47 per share from the same
INmune Bio Receives ~$4.2M Development Cash Rebate From Australia
This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. Β After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received